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DiSEASE, DiABETES MElliTuS, hYPERTENSiON
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ABSTRACT
The increasing burden of  chronic kidney disease and end stage kidney failure presents a challenge for both developed 
and emerging countries. While dialysis and transplantation consumes an ever-increasing proportion of  the health budget 
in countries such as the United States, Japan and Taiwan, there is limited availability of  these expensive therapies in the 
majority of  emerging countries and more so in African nations.
Aims: To review the prevalence, causes and integrated strategies for treatment and prevention of  end stage renal 
disease (ESRD) in Sub-Saharan Africa (SSA).
Materials and Methods: Review of  literature and information received from colleagues in Africa.
Results: Approximately 70% of  the least developed countries of  the world are in SSA. Rapid urbanisation is occurring 
in many parts of  the continent, contributing to overcrowding and poverty. While infections and parasitic diseases are 
still the leading cause of  death in Africa, non-communicable diseases are coming to the forefront. There is a continuing 
“brain drain” of  healthcare workers (physicians and nurses) from Africa to more affluent regions, resulting in large 
rural areas of  Africa having no health professionals to serve these populations. There are no nephrologists in many 
parts of  SSA; the numbers vary from 0.5 per million population (pmp) in Kenya to 0.6 pmp in Nigeria, 0.7 pmp in 
Sudan and 1.1 pmp in South Africa.
Chronic kidney disease (CKD) affects mainly young adults aged 20-50 years in SSA and is primarily due to hypertension 
and glomerular diseases. HIV-related chronic kidney disease is assuming increasing prominence and often presents 
late, with patients requiring dialysis. Diabetes mellitus affects 9.4-million people in Africa. The prevalence of  diabetic 
nephropathy is estimated to be 6-16% in SSA. The current dialysis treatment rate is <20pmp (and nil in many countries 
of  SSA), with in-centre haemodialysis the modality of  renal replacement therapy (RRT) for the majority. Transplantation 
is carried out in a few SSA countries: South Africa, Sudan, Nigeria, Mauritius, Kenya, Ghana and Rwanda, with most 
of  the transplants being living donor transplants, except in South Africa where the majority are from deceased donors. 
Prevention programmes are in their infancy in most of  SSA, due to lack of  personnel and resources.
Conclusion: Chronic kidney disease care is especially challenging in SSA, with large numbers of  ESRD patients, 
inadequate facilities and funding, and lack of  national or regional registries. Integrated management of  CKD and its 
risk factors is necessary to impact on the burden of  ESRD.
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mellitus, hypertension, glomerular disease) and resulting 
in the reduction of  kidney function, microalbuminuria, 
macroalbuminuria, end stage renal failure (ESRF) and 
death1.
In recent years, major social and demographic changes 
have taken place in Africa, with large numbers of  rural 
Black populations migrating to the cities, adopting a more 
western lifestyle, and being exposed to vascular risk factors 
with respect to diet, smoking habits, and level of  physical 
activity. Recent hospital morbidity and intensive care unit 
statistics in South Africa indicate that the prevalence of  
coronary heart disease (CAD) in urban Blacks is increasing2.
While the burden of  infections presents an enormous 
challenge in Sub-Saharan Africa (SSA), non-communicable 
diseases also constitute a major threat to the populations 
of  Africa. This “double burden” poses a public health 
and economic burden to developing countries. Infections 
and parasitic diseases are still the leading cause of  death 
in Africa, with over 5.5-million deaths in 2005 and over 
2-million deaths due to HIV/AIDS. Non-communicable 
diseases are coming to the forefront with over 2.4-million 
deaths in 20053. While communicable diseases are the 
leading cause of  death in low income countries, chronic 
diseases such as ischaemic heart disease and stroke feature 
at number two and four respectively4 and were the leading 
causes of  death in South Africa in the previous decade5. 
A more recent study showed that stroke and heart disease 
were the two leading causes of  death in 15-64-year-old 
Black South African men and women for the period 1999-
2006, with death from kidney disease featuring as the fifth 
leading cause of  death in this age group in 20066.
Chronic kidney disease and end stage renal disease
The lack of  renal registries means that there are no reliable 
statistics about the prevalence of  chronic kidney disease 
(CKD) and end stage renal disease (ESRD) in the majority 
of  African countries. Calculations suggest that CKD must 
be in the range of  200-300 per million of  the general 
population.
Chronic kidney disease is prevalent in Nigeria, account-
ing for 8-12% of  hospital admissions7, and affects mainly 
young adults aged 20-50 years in SSA and is primarily due 
to hypertension and glomerular diseases. However, in de-
veloped countries CKD presents in middle-aged and el-
derly patients and is predominantly due to diabetes mellitus 
and hypertension.
Chronic kidney disease has been shown to confer in-
creased risk for cardiovascular (CV) death. The Women’s 
Health Study of  ±40,000 healthcare workers aged >45y in 
the United States reported that 1,199 CV events and 856 
deaths occurred over 12 years. There were 1,315 women 
with eGFR<60ml/min/1.73m2 and an increased risk of  
CV death with hazard ratio (HR) of  1.68. Average demo-
graphics of  the study population (age 55, total cholesterol 
5.5 mmol/l, HDL cholesterol 1.4mmol/l, not diabetic, 
non-smoker, systolic BP 124mmHg) suggested that the in-
creased CV risk was due to a decrease in renal function8.
The Framingham study showed increased CV and all cause 
mortality according to proteinuria status in men and wom-
en aged 35-74 years over 16 years of  follow up9.
Major risk factors for chronic kidney disease in Africa
Hypertension
In the South African Demographic Health Survey of  
over 13,000 adults, hypertension prevalence was 21.3%, 
with <50% treated and <1/3 controlled 5. Hypertension 
is a leading cause of  CKD in SSA ranging from 25% 
in Senegal, 29.8% in Nigeria, 45.6% in South Africa 
and 48.7% in Ghana, especially in Black patients10. 
Hypertension affects about 25% of  the adult population 
and is the cause of  ESRD in 21% of  patients on renal 
replacement therapy in South Africa11. The clinical pattern 
of  hypertension in hospitalised patients takes a rapid 
course with uraemia and death, frequently from cerebral 
haemorrhage. Malignant hypertension was an important 
cause of  morbidity and mortality among urban Black South 
Africans with hypertension accounting for 16% of  all 
hospital admissions12 and seems to be of  lesser frequency 
in the present era.
Glomerulonephritis
Glomerular disease is common in Africa and is a major 
cause of  ESRD in reports from SSA. Reports from different 
areas of  Africa display differences in the prevalence of  
patterns of  glomerular injury. For example, in Nigerian 
children with nephrotic syndrome, membranoproliferative 
patterns on biopsy predominate, whereas in series from 
South Africa FSGS seems to be commonest13, 14. Although 
epidemiologic data from many areas in Africa is sparse, 
the incidence of  glomerular disease, particularly nephrotic 
syndrome, seems to be many times higher in Africa. 
Glomerular disease is more prevalent in Africa and seems 
to be of  a more severe form than that found in western 
countries, and is characterised by poor response to 
treatment and progression to renal failure. 
One success story is the impact of  hepatitis B vaccination 
in South Africa; prior to the availability of  the vaccine, 
hepatitis B virus (HBV) infections accounted for over 
80% of  membranous nephropathy in Black children15. 
Following vaccination, there were no cases of  membranous 
nephropathy due to HBV reported in the 0-4 year age 
group16.
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HIV chronic kidney disease
HIV infection is epidemic in SSA. The number of  new 
infections is now declining, with increasing numbers of  
patients on anti-retroviral therapy 17. Data on the prevalence 
of  HIV-related glomerular disease in Africa is scarce. This 
relates to the late presentation in Africa of  patients with the 
disease; often patients are dialysis-requiring at presentation. 
Reported prevalence of  CKD in HIV-infected ART-naïve 
patients in SSA ranges from 6-45% (Table 1) 18. Screening 
studies in South Africa reported proteinuria in 5.5-6%, with 
HIV-associated nephropathy (HIVAN) on biopsy in 5-83%19, 
20. Recent studies showed that the risk for HIVAN is linked 
to the MYH9 gene polymorphism, with the risk variant 
accounting for all or nearly all of  the increased risk for 
FSGS (80%) and HIV-associated collapsing glomerulopathy 
(100%) that characterise African Americans 21, 22. The APOL1 
variant was reported to be strongly associated with the 
collapsing glomerulopathy of  HIV-associated nephropathy 
in African Americans 23. An escalating burden of  HIV CKD 
may be anticipated, with increasing life expectancy on ART, 
ageing of  HIV-infected populations and nephrotoxicity of  
the various drugs used in this population. Following ART, 
renal function improved24, with renal survival dependent 
on virological response to therapy25. Lack of  response was 
attributed to a high index of  chronic damage in a study of  
61 patients with HIVAN presenting with advanced CKD at 
the time of  diagnosis and initiation of  ART, 56% of  whom 
reached ESRD in a median time of  4.2 years26. The response 
of  both microalbuminuria (MA) and proteinuria to ART was 
rapid and sustained, resolving to normal limits within 3-6 
months27.
Diabetes mellitus
There are 135-million diabetics worldwide, with a projected 
increase to 300-million by 2025 and to increase by 170% 
in developing countries (± 40% in developed countries) 28. 
Diabetes mellitus affects 9.4-million people in Africa. The 
estimated increase in diabetes mellitus in Africa is anticipated 
to be 12.7-million, an increase of  140%, by 2025. The 
prevalence of  diabetic nephropathy is estimated to be 6-16% 
in SSA29. Forty percent of  diabetics are at risk of  overt 
nephropathy. Diabetic patients with renal disease have a five 
to six-fold increased mortality rate compared to diabetic 
patients with no signs of  renal disease, or healthy subjects. 
Cardiovascular risk is increased in diabetics according to 
the level of  proteinuria30 and presence of  hypertension.32 
Renoprotective strategies have been well-described and 
include glycaemic control, blood pressure control, anti-
proteinuric drugs (rennin angiotensin system blockade and 
aldosterone antagonists), cessation of  smoking, a diet low in 
salt and saturated fats, exercise and weight control and anti-
platelet therapy (Table 2). 
Resources for nephrology care
There is a continuing “brain drain” of  healthcare workers 
(physicians and nurses) from Africa to more affluent 
regions32, resulting in large rural areas of  Africa having no 
health professionals to serve these populations. Table 3 
shows the distribution of  physicians and nephrologists in a 
spectrum of  SSA countries and their corresponding rates of  
renal replacement therapy (RRT). There are no nephrologists 
in many parts of  SSA; the numbers vary from 0.5 pmp in 
Kenya to 0.6 per million population (pmp) in Nigeria, 0.7 
pmp in Sudan, 1.1 pmp in South Africa33. The United States 
had 16.7 nephrologists pmp and optimal numbers are 30 
nephrologists pmp.
Renal replacement therapy
The availability of  RRT is limited in much of  Sub-Saharan 
Africa due to high costs and a shortage of  skilled personnel, 
and is responsible for the high rates of  morbidity and 
mortality. Most dialysis centres are situated in cities, placing 
a further burden on patients who often have to travel long 
distances to get treatment. In-centre haemodialysis is the 
modality of  RRT for the majority of  African countries. 
Many patients are under-dialysed; only 20% of  patients in 
a Nigerian centre could afford to have dialysis three times 
a week, and 70% could only afford it once a week3. As the 
majority are self-funded, very few are able to sustain chronic 
dialysis beyond six months.
Renal replacement therapy was accessed by approximately 
1.8-million people worldwide in 2004; less than 5% of  the 
dialysis population was from SSA. The current dialysis 
treatment rate ranges from <20 per million population 
(pmp) for most of  SSA (and nil in many countries of  SSA) 
to 421 pmp in Egypt; the corresponding figures for Japan 
being 1,940 pmp, USA 1,090 pmp and Germany 800 pmp. 
Dialysis rates were 45 pmp for haemodialysis (HD) and 23 
pmp for CAPD in South Africa; 46 pmp for HD and 3 pmp 
for CAPD in Sudan and 7.5 pmp for HD and 1.2 pmp for 
CAPD in Kenya compared to 421 pmp for HD and 0.3 
pmp for CAPD in Egypt, 650 pmp for HD and 20 pmp for 
CAPD in Tunisia33. Availability of  CAPD is limited in Sub-
Saharan Africa because of  the high cost of  dialysis fluids and 
a perception of  a high rate of  peritonitis. The average cost of  
haemodialysis in Africa is $100 per session. The annual costs 
of  CAPD are equivalent to that of  in-centre haemodialysis.
Transplantation is carried out in a few SSA countries: South 
Africa, Sudan, Nigeria, Mauritius, Kenya and Ghana, with 
most of  the transplants being living donor transplants, 
except in South Africa where deceased donor transplants 
are carried out to a greater extent (80% deceased donors 
and 20% living donors respectively). Deceased donation is 
hampered in many countries by a lack of  a legal framework 
governing brain death, and religious and social constraints. 
The transplant rate in Africa averages 4 pmp and is 9.2 pmp 
in South Africa35.
Funding for RRT is primarily private in much of  Africa, with 
the governments of  only a few countries providing RRT for 
small number of  patients (e.g. Cameroon, Mali, Mauritius, 
Rwanda, Sudan, South Africa); indigent South Africans are 
able to access chronic dialysis at governmental cost only 
if  they are eligible for transplantation. In many African 
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countries, chronic dialysis is not sustainable, with patients 
unable to afford dialysis beyond the first 2-3 months.
Strategies for Africa
The above highlights the important facts of  chronic disease 
epidemiology in Africa with tremendous public health 
ramifications. Hypertension, diabetes, coronary heart disease 
and ESRD are on the verge of  becoming an epidemic in 
Africa with urbanisation. Treatment for all affected is 
beyond the reach of  most countries in Africa. The only 
cost effective and sustainable means is prevention. How can 
Africa prevent or curtail the increasing prevalence of  these 
non-communicable conditions?
Primary prevention strategies
Effective prevention and management of  chronic conditions 
requires a co-ordinated, comprehensive healthcare system 
involving self-management and regular follow-up. Public 
education at an early stage – at schools – and on a continual 
basis, with active media participation to promote healthy 
living, as well as financial and other incentives, would result 
ultimately in healthier populations. Countries like South 
Africa have legislated successfully against smoking in public 
places.
Immunisation has played an important role in disease 
prevention. Inclusion of  hepatitis B vaccination in the 
extended programme of  immunisation in South Africa 
in 1995 has impacted on the prevalence of  membranous 
nephropathy due to this aetiology in children.
Secondary prevention strategies
The majority of  patients with CKD present with terminal 
uraemia, requiring emergency dialysis. Screening of  high-risk 
populations for CKD (Table 4) is a strategy that should be 
implemented, directed at patients with hypertension, diabetes 
mellitus, proteinuria, HIV infection (Table 5), the elderly, and 
those with a family history of  chronic kidney disease. Simple 
screening tests such as urinalysis and measurement of  serum 
creatinine, with calculation of  GFR are important initial 
investigations to identify CKD. It is important for different 
regions to validate formulae for estimating GFR for their 
populations.
Conclusion
Provision of  RRT is especially challenging in SSA. 
Nephrologists and physicians are faced with large numbers 
of  ESRD patients, inadequate facilities, funding and support. 
While prevention strategies are recognised as optimal 
therapy in managing CKD, it is still in its infancy in much of  
SSA, mainly due to lack of  healthcare workers and funding. 
Prevention of  renal disease by early detection of  its risk 
factors, delaying the progression of  CKD in those patients 
with renal damage and attending to cardiovascular risk 
factors, as well as timely planning for RRT in those patients 
reaching ESRD, is essential in the integrated management of  
CKD and its risk factors, and is necessary to impact on the 
burden of  ESRD.
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Table 1. Prevalence of  hiV Chronic Kidney Disease
Sub-Saharan Africa Global
Country Prevalence (%) Country Prevalence (%)
South Africa  5.5 - 6 United States 3.5 - 12
Nigeria 38 Europe, Israel, Argentina 3.5 - 4.7
Cote d’Ivoire 26 Hong Kong 18
Tanzania 28.4 Brazil 1.1 - 5.6
Kenya 25 Switzerland 18
Uganda 20 - 48.5 India 27
Zambia 33.5 Iran 20
Table 2. Renoprotection in Diabetes Mellitus
 ● Glycaemic control: HbA1C<7%
 ● Blood pressure control <130/80
 ● Anti-proteinuric agent: 
 ○ RAS blockade (ACEI; ARB)
 ○ Aldosterone antagonists
 ● Other measures:
– Dietary: limit salt and saturated fats
– Stop smoking
– Lipid lowering
– Exercise and weight control
– Antiplatelet therapy
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Table 3. Distribution of  Physicians, Nephrologists and Renal Replacement Therapy in Some Sub-Saharan African 
Countries





No PMP No PMP No/year 
Nigeria 34923 3 70 0.6 1000 8 0 70
Ghana 3240 2 2 0.1 35 2 0 0
Senegal 594 <1 2 0.2 50 4.2 26 1 0
Sudan 11083 3 25 0.7 1610 46 111 3 74
Kenya 4506 1 15 0.5 260 7.5 30 1.2 10
Rwanda 432 <1 1 0 30 3.7 18
South Africa 34829 8 50 1.1 2070 45 1058 23 240
Abbreviations: No = number; Neph = nephrologists; RRT = renal replacement therapy; HD = haemodialysis;
CAPD = continuous ambulatory peritoneal dialysis; TP = transplants; PMP = per million population
Table 4. Screening for Chronic Kidney Disease




– Family history of  chronic kidney disease 
– Older age group
 ● Screening tests
– Urine: protein creatinine ratio; haematuria
– Serum creatinine→ eGFR
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Table 5. Recommendation: Screening for hiV Chronic Kidney Disease
 ● All patients diagnosed with HIV infection should be screened for proteinuria and kidney function at presentation, and 
annually if  high risk
 ● High risk for HIV-related nephropathy
 ○ African descent
 ○ Low CD4 counts
 ○ High viral loads
 ○ Patients with DM, HPT, HCV co-infection
 ○ 1°/2° relative with ESRD (5.4x increased risk)
Adapted from Gupta et al, Clin Infect Dis, June 2005
